Name: UMIN ID:
Unique ID issued by UMIN | UMIN000019436 |
---|---|
Receipt number | R000022471 |
Scientific Title | Randomized Phase 2 study of Nintedanib and Pirfenidone versus Nintedanib following a clinically meaningful decline in forced vital capacity in patients with idiopathic pulmonary fibrosis administering pirfenidone |
Date of disclosure of the study information | 2015/10/21 |
Last modified on | 2018/10/27 10:34:43 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/10/21 15:21:03 | ||
2 | Update | 2015/12/16 20:12:15 | Public title Acronym |
|
3 | Update | 2016/04/20 08:48:59 | Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
4 | Update | 2016/04/20 08:51:43 | Key inclusion criteria Key inclusion criteria |
|
5 | Update | 2016/04/20 08:54:16 | Name of primary person or sponsor Department Organization Organization |
|
6 | Update | 2016/04/20 08:55:16 | Recruitment status |
|
7 | Update | 2018/01/17 06:46:20 | Recruitment status |
|
8 | Update | 2018/10/27 09:43:53 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria |
|
9 | Update | 2018/10/27 10:34:43 | Recruitment status Anticipated trial start date |